Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,092 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel semi-quantitative scoring method for CD8+ tumor-infiltrating lymphocytes based on infiltration sites in gastric cancer.
Nakabayashi Y, Kiuchi J, Kubota T, Ohashi T, Nishibeppu K, Imamura T, Nanishi K, Shimizu H, Arita T, Yamamoto Y, Konishi H, Morimura R, Komatsu S, Shiozaki A, Ikoma H, Kuriu Y, Fujiwara H, Tsuda H, Otsuji E. Nakabayashi Y, et al. Among authors: komatsu s. Am J Cancer Res. 2024 Dec 25;14(12):5965-5986. doi: 10.62347/JKCU5881. eCollection 2024. Am J Cancer Res. 2024. PMID: 39803654 Free PMC article.
Chemokine (C-C Motif) Ligand 2/CCR2/Extracellular Signal-Regulated Kinase Signal Induced through Cancer Cell-Macrophage Interaction Contributes to Hepatocellular Carcinoma Progression.
Ishihara N, Koma YI, Omori M, Komatsu S, Torigoe R, Yokoo H, Nakanishi T, Yamanaka K, Azumi Y, Tsukamoto S, Kodama T, Nishio M, Shigeoka M, Yokozaki H, Fukumoto T. Ishihara N, et al. Among authors: komatsu s. Am J Pathol. 2025 Jan 3:S0002-9440(24)00480-2. doi: 10.1016/j.ajpath.2024.12.007. Online ahead of print. Am J Pathol. 2025. PMID: 39756577 Free article.
Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Ishihara N, Komatsu S, Yano Y, Fujishima Y, Ishida J, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Matsuura T, Tada T, Kodama Y, Fukumoto T. Ishihara N, et al. Among authors: komatsu s. Anticancer Res. 2025 Jan;45(1):251-260. doi: 10.21873/anticanres.17412. Anticancer Res. 2025. PMID: 39740814
2,092 results